Viking Therapeutics Is Ready For A Standalone Future
Portfolio Pulse from
Viking Therapeutics has secured a supply deal with CordenPharma for its obesity treatment VK2735, indicating a focus on a standalone future rather than a buyout.
March 12, 2025 | 11:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Viking Therapeutics has entered a supply agreement with CordenPharma for VK2735, suggesting a strategic move towards a standalone future in the obesity market, reducing the likelihood of a buyout.
The supply deal with CordenPharma for VK2735 positions Viking Therapeutics to independently pursue the obesity market, reducing buyout speculation and potentially increasing investor confidence in its growth prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100